Anavex Life Sciences Corp., incorporated on January 23, 2004, is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including drug candidates to treat Alzheimer's disease (AD), other central nervous system (CNS) diseases, pain and various types of cancer. Its research and development pipeline includes a clinical drug candidate and various compounds in different stages of pre-clinical study. Its product pipeline also includes ANAVEX 2-73, ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1037 and ANAVEX 1066. The Company's SIGMACEPTOR Discovery Platform produces small molecule drug candidates with modes of action, based on its understanding of sigma receptors. As of September 30, 2016, the Company had not generated any revenues from its operations.
ANAVEX 2-73
The Company's lead compound, ANAVEX 2-73, is being developed to treat AD, Parkinson's disease and other CNS diseases, including rare diseases, such as Rett syndrome. The preclinical data validates ANAVEX 2-73 as a platform drug for other neurodegenerative diseases beyond AD, as well as neurodevelopmental diseases, specifically, Parkinson's disease, epilepsy and Rett syndrome.
ANAVEX 3-71
The Company's ANAVEX 3-71 is a preclinical drug candidate with a mechanism of action through sigma-1 receptor activation and M1 muscarinic allosteric modulation, which has been shown to enhance neuroprotection and cognition in AD. ANAVEX 3-71 is a CNS-penetrable mono-therapy that bridges treatment of both cognitive impairments with disease modifications.
ANAVEX 1-41
The Company's ANAVEX 1-41 is a sigma-1 agonist. Pre-clinical tests have revealed neuroprotective benefits (protects nerve cells from degeneration or death) through the modulation of endoplasmic reticulum, mitochondrial and oxidative stress. In addition, in animal models, ANAVEX 1-41 prevented the expression of caspase-3, an enzyme that plays a role in apoptosis (programmed cell death) and loss of cells in the hippocampus, the part of the brain that regulates learning, emotion and memory. These activities involve both muscarinic and sigma-1 receptor systems through a mechanism of action.
ANAVEX 1037
The Company's ANAVEX 1037 is designed for the treatment of prostate cancer. ANAVEX 1037 is a low molecular weight, synthetic compound exhibiting high affinity for sigma-1 receptors at nanomolar levels, and moderate affinity for sigma-2 receptors and sodium channels at micromolar levels. It has also been shown to selectively kill human cancer cells without affecting normal/healthy cells and also to suppress tumor growth in immune-deficient mice models.
ANAVEX 1066
The Company's ANAVEX 1066 is a mixed sigma-1/sigma-2 ligand designed for the treatment of neuropathic pain and visceral pain. As of September 30, 2016, ANAVEX 1066 was tested in two preclinical models of neuropathic and visceral pain that had been validated in rats. In the chronic constriction injury (CCI) model of neuropathic pain, a single oral administration of ANAVEX 1066 dose-dependently restored the nociceptive threshold in the affected paw to normal levels while leaving the contralateral healthy paw unchanged. In a model of visceral pain, chronic colonic hypersensitivity was induced by injection of an inflammatory agent directly into the colon and a single oral administration of ANAVEX 1066 returned the nociceptive threshold to control levels in a dose-dependent manner.
The Company competes with Biogen, Axovant Sciences Ltd., Perrigo Company Plc, Pfizer Inc., Allergan Plc, Novartis AG, GlaxoSmithKline Plc, Merck & Co. Inc., Eli Lilly & Co., Johnson & Johnson and Roche Holding AG.
51 W 52nd St Fl 7th
The company trades on NASDAQ exchange. The company headquarter is located in New York, NY. The company was established in the 2006.| Ticker | AVXL |
| Long Name | Anavex Life Sciences Corp. |
| Short Name | Anavex Life Sciences |